Physician profile
Fabian E Espinosa
NPI 1922028224
$3,025.14
in general payments reported to CMS, 2019-2025
24 companies · $648 in 2025
The $648 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $86.48 · 2021: $331 · 2022: $369 · 2023: $724 · 2024: $331 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $776.24 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $646.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $570.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.30 | 2019-2023 | Tradjenta, Trijardy Xr, Synjardy |
| Merck Sharp & Dohme LLC | $157.23 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Nevro Corp. | $127.60 | 2023 | Senza |
| Pfizer INC. | $89.21 | 2019-2024 | |
| Dexcom, INC. | $68.00 | 2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $51.17 | 2019 | |
| Glaxosmithkline, LLC. | $49.04 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $43.37 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.64 | 2022-2024 | |
| Abbvie INC. | $32.73 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $27.01 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.34 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.99 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $19.73 | 2023 | Quviviq |
| Radius Health, INC. | $19.45 | 2019 | |
| Amgen INC. | $18.82 | 2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $18.62 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.60 | 2019 | |
| Astellas Pharma US INC | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabian Espinosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.